Syncom Formulation (India) Ltd

Fri 18/09/2026,15:54:25 | NSE : SYNCOMF

₹20.041.26 (6.71%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 18.80

Previous Close

₹ 18.78

Volume

10260524

Mkt Cap ( ₹ Cr)

₹ 1883.76

High

₹ 20.25

Low

₹ 18.80

52 Week High

₹ 22.59

52 Week Low

₹ 10.21

Book Value Per Share

₹ 4.68

Dividend Yield

0.53

Face Value

₹ 1.00

What's Your Call?

Collective community sentiment on Syncom Formulation (India) Ltd

Your Vote -

Buy

76.85%

Hold

17.24%

Sell

5.91%

76.85%

1827 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

20.04

1536

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

1536

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Syncom Formulation (India) Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Syncom Formul. - Corporate Announcement/Information Under Regulation 42 Of SEBI (LODR) Regulations, 2015 Regarding Record Dat

    18 Sep 2026, 11:49AM We are pleased to inform you that, pursuant to the provision of regulation 42 of SEBI (LODR) regulation, 2015 and section 91 of companies Act, 2013 th
  • Syncom Formul. - Copy of Newspaper Publication

    8 Sep 2026, 4:49PM Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication
  • Syncom Formul. - General Updates

    7 Sep 2026, 7:28PM Syncom Formulations (India) Limited has informed the Exchange about General Updates
  • Syncom Formul. - General Updates

    7 Sep 2026, 7:26PM Syncom Formulations (India) Limited has informed the Exchange about General Updates
  • Syncom Formul. - Shareholders meeting

    7 Sep 2026, 7:20PM Syncom Formulations (India) Limited has informed the Exchange about Shareholders meeting
  • Syncom Formul. - Regulation 36(1)(B) Of The SEBI (LODR) Regulations, 2015- Dispatch Of Letters To Shareholders Who Have Not R

    7 Sep 2026, 7:06PM Pursuant to Reg 36(1)(b) of SEBI (LODR) Regulation, 2015, we hereby inform that company has dispatched the letters to shareholders whose email address
  • Syncom Formul. - Business Responsibility and Sustainability Reporting (BRSR)

    7 Sep 2026, 6:53PM Submission of Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26 pursuant to regulation 34(2)(f) of SEBI (LODR) R
  • Syncom Formul. - Submission Of The Notice Of 38Th Annual General Meeting To Be Held On Wednesday 30Th September, 2026.

    7 Sep 2026, 6:46PM We are pleased to submit herewith a copy of the Notice of the 38th AGM of the company, scheduled to be held on Wednesday, 30th day of September, 2026
  • Syncom Formul. - Reg. 34 (1) Annual Report.

    7 Sep 2026, 6:39PM Submission of 38th Annual Report along with the Notice of Annual General Meeting to be held on Wednesday, 30th September, 2026 through Video Conferenc
  • Syncom Formul. - Copy of Newspaper Publication

    1 Sep 2026, 3:43PM Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication
  • Syncom Formul. Q1 net profit jumps 56.33% at Rs 24.59 cr

    26 Aug 2026, 6:40PM The company reported standalone net profit of Rs 24.59 crore for the quarter ended June 30, 2026 as compared to Rs 15.73 crore in the same period last
  • Syncom Formul. has declared 10% Final dividend for the financial year March 2026

    13 Aug 2026, 6:31PM Syncom Formulation (India) Ltd. on Tuesday, 11 August 2026, has announced Final dividend of 10 percent on Equity Share, to its shareholders holding sh
  • Syncom Formul. - General Updates

    13 Aug 2026, 5:48PM Syncom Formulations (India) Limited has informed the Exchange about General Updates
  • Syncom Formul. - Disclosure of material issue

    13 Aug 2026, 5:08PM Syncom Formulations (India) Limited has informed regarding Disclosure of material issue
  • Syncom Formul. - Disclosure of material issue

    13 Aug 2026, 5:03PM Syncom Formulations (India) Limited has informed regarding Disclosure of material issue
  • Syncom Formul. - Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015('Listing Regul

    13 Aug 2026, 5:52PM PURSUANT TO REG 30 SEBI, LODR, WE HEREBY SUBMIT THE PRESS RELEASE ISSUED BY THE COMPANY
  • Syncom Formul. - Copy of Newspaper Publication

    12 Aug 2026, 3:29PM Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication
  • Syncom Formul. - Resignation of Director/KMP/SMP

    11 Aug 2026, 7:24PM Syncom Formulations (India) Limited has informed the Exchange about Resignation of Director/KMP/SMP
  • Syncom Formul. - Change in Management

    11 Aug 2026, 7:19PM Syncom Formulations (India) Limited has informed the Exchange about change in Management
  • Syncom Formul. - Announcement under Regulation 30 (LODR)-Change in Management

    11 Aug 2026, 7:18PM Disclosure under Regulation 30(2) read with Clause 7 of Para A of Schedule /// of the SEBI (LODR) Regulation, 2015: Change in directors, KMP and Senio
  • Syncom Formul. - General Updates

    11 Aug 2026, 7:15PM Syncom Formulations (India) Limited has informed the Exchange about General Updates
  • Syncom Formul. - Corporate Announcement/Information Pursuant To Regulation 44 Of The SEBI (LODR) Regulations, 2015

    11 Aug 2026, 7:14PM Corporate Announcement/Information pursuant to Regulation 44 of the SEBI (LODR) Regulation, 2015 regarding providing Remote E-Voting facilities for th
  • Syncom Formul. - Change in Auditors

    11 Aug 2026, 7:07PM Syncom Formulations (India) Limited has informed the Exchange regarding Change in Auditors of the company.
  • Syncom Formul. - Disclosure Pursuant To Regulation 30 Read With Schedule III Of The SEBI (LODR) Regulations, 2015.

    11 Aug 2026, 7:01PM Appointment of Cost Auditor and Internal Auditor for the FY 2026-27.
  • Syncom Formul. - Outcome of Board Meeting

    11 Aug 2026, 6:49PM Regulation 33(3) of SEBI (LODR) Regulations, 2015- Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Revie
  • Syncom Formul. - Regulation 33(3) Of SEBI (LODR) Regulations, 2015- Submission Of The Un-Audited Standalone And Consolidated

    11 Aug 2026, 6:23PM Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Un-Audited Standalone and Consolidated Financial Results a
  • Syncom Formul. - Record Date

    11 Aug 2026, 6:11PM Syncom Formulations (India) Limited has informed the Exchange that Record date for the purpose of Dividend & Meeting is 23-Sep-2026.
  • Syncom Formul. - Dividend

    11 Aug 2026, 6:08PM Syncom Formulations (India) Limited has informed the Exchange that Board of Directors at its meeting held on August 11, 2026, recommended Final Divide
  • Syncom Formul. - Outcome of Board Meeting

    11 Aug 2026, 6:05PM Outcome of the 2/2026-27 Meeting of the Board of Directors of the Company held on Tuesday, 11th August 2026 pursuant to Regulation 30 read with Schedu
  • Syncom Formul. - Corporate Action-Board approves Dividend

    11 Aug 2026, 5:54PM We are pleased to inform you that, pursuant to the provision of Regulation 42 of SEBI (LODR) Regulations, 2015 and Section 91 of the Companies Act, 20
  • Syncom Formul. - Board Meeting Outcome for Outcome Of The 2/2026-27 Meeting Of The Board Of Directors Of The Company.

    11 Aug 2026, 5:46PM Outcome of the 2/2026-27 Meeting of the Board of Directors of the Company held on Tuesday, 11th August 2026 pursuant to Regulation 30 read with Schedu
  • Syncom Formul. - Announcement under Regulation 30 (LODR)-Resignation of Managing Director

    10 Aug 2026, 6:18PM Revised Intimation for resignation of Mr. Vijay Shankarlal Bankda Managing Director Under Regulation 30 of SEBI (LODR) Regulations, 2015.
  • Syncom Formul. - Disclosure of material issue

    8 Aug 2026, 2:57PM Intimation for resignation of Mr. Vijay Shankarlal Bankda Managing Director- Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure
  • Syncom Formul. - Disclosure of material issue

    8 Aug 2026, 2:34PM Intimation for resignation of Mr. Rahul Vijay Bankda Chief Financial Officer (CFO)- under Regulation 30 of SEBI (Listing Obligations & Disclosure Requ
  • Syncom Formul. - Disclosure of material issue

    8 Aug 2026, 1:33PM Intimation for resignation of Mr. Kedarmal Shankarlal Bankda Whole-Time Director- under Regulation 30 of SEBI (Listing Obligations & Disclosure Requir
  • Syncom Formul. - Announcement under Regulation 30 (LODR)-Resignation of Managing Director

    8 Aug 2026, 3:01PM Intimation for Resignation of Mr. Vijay Shankarlal Bankda Managing Director under Regulation 30 of SEBI (LODR) Regulations, 2015
  • Syncom Formul. - Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)

    8 Aug 2026, 1:19PM Intimation for Resignation of Mr. Rahul Vijay Bankda Chief Financial Officer (CFO) under Regulation 30 of SEBI (Listing Obligation & Disclosure Requir
  • Syncom Formul. - Announcement under Regulation 30 (LODR)-Resignation of Director

    8 Aug 2026, 1:16PM Intimation for Resignation of Mr. Kedarmal Shankarlal Bankda Whole-Time Director under Regulation 30 of SEBI (Listing Obligation & Disclosure Requirem
  • Syncom Formul. - Corporate Action-Board to consider Dividend

    6 Aug 2026, 6:00PM Pursuant to Regulation 29(1)(a) of SEBI (LODR) Regulation 2015, we are pleased to inform that 2/2026-27 Meeting of the Board of Directors of the compa
  • Syncom Formul. - Board Meeting Intimation for Corporate Announcement U/R 29(1)(A) Of SEBI (LODR) Regulations, 2015 Read With

    6 Aug 2026, 5:54PM Syncom Formulations India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to co
  • Syncom Formul. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    20 Jul 2026, 7:50PM As of June 2026, 50.57% is owned by Indian Promoters and 49.43% by Public. <p align=justify> Top five Promoters holding highest number of shares of Sy
  • Syncom Formul. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    10 Jul 2026, 12:36PM Syncom Formulations (India) Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Syncom Formul. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    10 Jul 2026, 12:32PM Certificate for compliance of regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th June, 2026
  • Syncom Formul. - Trading Window

    25 Jun 2026, 1:49PM Syncom Formulations (India) Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) R

Key fundamentals

Evaluate the intrinsic value of Syncom Formulation (India) Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 412.9858 343.947 358.1021 339.1962 280.0124
Liabilities 412.9858 343.947 358.1021 339.1962 280.0124
Equity 94 94 94 94 86.2453
Gross Profit 77.159 53.5053 27.8543 19.6132 19.4629
Net Profit 76.008 48.8718 23.6232 20.0707 19.7904
Cash From Operating Activities 58.292 23.3133 -5.9376 10.4962 16.329
NPM(%) 15.62 10.55 9.14 8.93 9
Revenue 486.5728 462.8493 258.3596 224.6439 219.6632
Expenses 409.4138 409.344 230.5053 205.0307 200.2003
ROE(%) 17.28 11.11 5.37 4.56 4.49

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
23 Sep 2026 0.1 10 0.5 14.53

Peers

Other companies within the same industry or sector that are comparable to Syncom Formulation (India) Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 833.60 -0.58 21.08 10.73 -26.19 0.60
Lotus Eye Hospital and Institute Ltd 115.10 1.75 1644.29 39.10 0.39 0.00
Vaishali Pharma Ltd 8.79 0.11 27.47 245.27 15.42 0.00
Astec Lifesciences Ltd 726.70 -3.77 0.00 41.89 -363.14 0.00

Company Info

Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.

Syncom Formulations (India) Limited - a renowned name in the Indian Pharmaceutical Industry represents SYNergistic COMbination for health. -Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur (30kms away from Indore, the commercial capital of Madhya Pradesh, India). Established in the year 1995, Syncom's state of art WHO-GMP and ISO 9001-2015 certified plant is geared up with latest production machineries and maintains high quality standards. Currently pharmaceutical formulation products SYNCOM manufactures and markets more than 500 products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials & Ampoule Injections & Dry powder injections, Ophthalmic preparations, Dry Syrups and suspensions , Ointments, Creams, Gel , ORS & Jelly 1988 -Syncom Formulation (India) Ltd. was established. 2005 -Company had allotted 2.65lakh fully paid-up equity shares of Rs 10 each at a premium of Rs 80 per share on the preferential basis. 2006 -Board of directors of the company had considered issue of 2.95 equity shares aggregating to Rs 1.59 crore on preferential basis. -The comapny approved an Rs 7.1 crore plan to install two wind mills of 0.60 MW each at Sangli in Maharashtra. 2008 -Board of directors of the company had approved amendment in the Articles of Association for insertion of clauses relating to authorizing the board for issuance of warrants convertible into equity shares of the company. -On 25th March 2008, board of directors of the company had transacted the allotment of 3.1 lakh equity shares of Rs 10 each by way of preferential allotment at a premium of Rs 36per equity share to Shri. Kedarmal Bankda, promoter of the company. -On the same date board of directors of the company had transacted the allotment of 3.25 lakh warrants of Rs 46 each. 2009 -Syncom Formulations India has recommended the dividend @ Rs. 0.50 (5%) on equity shares of Rs. 10/- each -Syncom Formulation (India) Ltd Issues Rights in the Ratio of 1:2 2011 -Mrs. Shikha Sethi, has been appointed as the Company secretary of the Company 2012 -Company has incorporated a Wholly Owned Subsidiary Company in the name of "TRADE ZONE FZE" in the United Arab Emirates -Shri. Praveen Jindal has been appointed as an Independent Director of the company. 2013 -The Company in the proportion of 5 (Five) Equity Shares of Rs. 1 (Rs. One) for every 2 (Two) Equity Shares of Rs. 1 (Rs. One) held by them on the record date as may be decided by the Board with the consultation of the Stock Exchange. -The Company has recommend a dividend Rs. 0.60 (Sixty paise) (6%) per equity share of Rs. 10/- each for the year 2012-13, -Syncom Formulation (India) has announces bonus in the ratio of 5:2 -Syncom Formulation (India) has splits its face value from Rs 10/- to 1/- 2014 -The Company has recommend a dividend of Rs. 0.02 (Two paise) (2%) per equity share of Re. 1/- each for the year 2013-14 -The Company has appointed Smt. Rinki Bankda in the category of Women Director as an Additional Director of the Company w.e.f. August 13, 2014. 2022 -Syncom Formulations (India) Limited has awarded 'PRODUCT EXCELLENCE 2022' under the category of 'Pharma (Medium)'organized.

Parent Organisation

Syncom Formulation (India) Ltd.

Founded

21/06/1988

Managing Director

Mr.Vijay Shankarlal Bankda

NSE Symbol

SYNCOMFEQ

FAQ